PressJune 22, 2022 Numinus Applies for International Patent Filing of Psychedelics Production Process
BlogJune 22, 2022 Kimberly Stuck Supports Businesses in Tightly Regulated Industries – Podcast Episode #9
PressJune 21, 2022 Lobe Sciences and Clearway Global Enter into Agreement to Manage Lobe Science’s Global Regulatory and Development Strategy and Implementation
PressJune 17, 2022 U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
PressJune 16, 2022 Nova Mentis Files Patent on Diagnosing, Monitoring and Treating Neurological Diseases with Psychoactive Tryptamine Derivatives
PressJune 15, 2022 Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Mental Health Disorders
BlogJune 15, 2022 Jay Godfrey and Richard Meloff are Unleashing the Power of Psychedelic Therapy – Podcast Episode #8
PressJune 14, 2022 Filament Health Cultivates 70th Variety of Psilocybin-containing Mushrooms At Vancouver Facility
PressJune 13, 2022 Mindset Pharma Receives Notice of Allowance for Patent Application for Psilocin Derivatives
BlogJune 10, 2022 Dr. Chris Witowski, CEO of Psilera Bioscience, Sits in the Investor Hotseat: Stream #2
PressJune 9, 2022 Tryp Therapeutics Announces Results of First Patient Dosed in Phase II Clinical Trial for Binge Eating Disorder
PressJune 8, 2022 Nova Mentis Receives Controlled Substances Export Approval From DEA For Proprietary Psilocybin Drug
